Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
May 2024—Sysmex America announced it will sell hemostasis instruments and reagents to laboratories in the United States under the company’s mutual original equipment manufacturer agreement with Siemens Healthineers. The agreement allows the companies to distribute hemostasis instruments provided by Sysmex and reagents provided by Siemens under their respective brands.
May 2024—Scopio Labs announced it has been granted de novo clearance by the FDA for its Full-Field Bone Marrow Aspirate application for use on the company’s X100 and X100HT platforms. The application is designed to assist users in streamlining bone marrow aspirate review and reporting. It automates the detection and visualization of hematopoietic cells in stained smears, facilitating evaluations such as bone marrow smear quality assessment, blast cell and plasma cell estimation, and calculation of the myeloid to erythroid ratio.
May 2024—Verichem Laboratories has upgraded its Web-based, CLIA-compliant data reduction and test reporting software. The new version allows customers to save reports on the company’s server for future editing and edit previous submissions for up to three days after the initial submission. Previous submissions are autosaved so users can edit data without rekeying or reentering any other component information. The software is available to customers at no cost.
May 2024—Newcomer Supply announced it is distributing HistoCyte Laboratories cell line controls for research use only. HistoCyte uses proprietary methods to process cell lines into tissue-like controls. The products are standardized, developed, and manufactured to provide consistent morphology and staining results throughout the FFPE block. Cell line controls are available as either precut slides or in cell microarray blocks.
April 2024—Diasorin announced FDA 510(k) clearance for its Liaison Plex platform and Flex respiratory assay. The fully automated, sample-to-answer system uses room-temperature–stable consumables and has a hands-on time of two minutes per sample. Results are available in less than two hours. Diasorin says Flex testing allows users to generate and pay for a subset of specific results based on a patient’s clinical picture.
April 2024—Roche announced FDA approval of the Cobas Malaria test, a qualitative in vitro nucleic acid screening test for the direct detection of Plasmodium RNA and DNA in whole blood samples from individual human donors. The test can be performed with other routine blood donor screening tests and is designed for use on the Cobas 6800/8800 systems in the United States.
April 2024—Verichem Laboratories offers a multilevel set of clinical reference materials intended for the calibration verification of clinical systems testing for total protein and albumin in urine and cerebrospinal fluid samples. The liquid-stable and ready-to-use materials are suitable for use with turbidimetric and colorimetric test methods and incorporate human protein components.
April 2024—Bayer and Thermo Fisher Scientific announced that they will develop next-generation sequencing–based companion diagnostic assays to help identify patients who may benefit from Bayer’s precision cancer therapies. The assays will be developed using Thermo Fisher’s Oncomine Dx Express test on the Ion Torrent Genexus Dx system. The Genexus Dx instrument and Oncomine Dx Express test are CE-IVD marked and only available in countries that accept the CE mark.
April 2024—Technoclone and its distributor in the United States, DiaPharma Group, announced that the FDA has granted de novo classification for the Technozym ADAMTS13 Activity ELISA. The assay is intended for the qualitative determination of ADAMTS13 activity in platelet poor human citrated plasma and indicated for use in conjunction with other clinical and laboratory findings as an aid in diagnosing thrombotic thrombocytopenic purpura in adult and pediatric patients being evaluated for thrombotic microangiopathy.
April 2024—Bio-Rad Laboratories announced it received My Green Lab certification for its R&D facilities in Irvine, Calif. It has been certified at My Green Lab’s highest rating, green, which reflects the percentage of possible green lab best practices that have been adopted and the extent to which they have been adopted by the lab.
